CER-1236

News alerts, weekly reports and conference planners

Company:

CERo Therap

Drug class:

T-cell stimulant

Related drugs:

‹

›

10ms

Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross presentation. (PubMed, Mol Ther)

We also show that activated CER-1236 T cells exhibit superior cross-presentation ability compared to conventional T cells, triggering E7-specific TCR-T responses in an HLA class I and TLR-2 dependent manner, thereby overcoming the limited antigen presentation capacity of conventional T cells. Therefore, CER-1236 T cells have the potential to achieve tumor control by eliciting both direct cytotoxic effects and indirect-mediated cross-priming.

10 months ago

Journal

TLR2 (Toll Like Receptor 2)

EGFR mutation

CER-1236